— Know what they know.
Not Investment Advice

SCPH NASDAQ

scPharmaceuticals Inc.
1W: +0.2% 1M: +0.9% 3M: +26.9% 1Y: +32.5% 3Y: -10.6% 5Y: -24.4%
$5.67
Last traded 2025-10-08 — delisted
NASDAQ · Healthcare · Biotechnology · $302.2M mcap · 33M float · 4.43% daily turnover · Short 27% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$302.2M
52W Range1.94-6.28
Volume10,898,632
Avg Volume1,449,396
Beta0.30
Dividend
Analyst Ratings
5 Buy 3 Hold 0 Sell
Consensus Buy
Company Info
CEOJohn H. Tucker
Employees162
SectorHealthcare
IndustryBiotechnology
IPO Date2017-11-17
2400 District Avenue
Burlington, MA 01803
US
617 517 0730
About scPharmaceuticals Inc.

scPharmaceuticals Inc. is a pharmaceutical firm dedicated to developing and commercializing a variety of medicinal products. Its primary investigational therapy, FUROSCIX, is a specialized formulation of furosemide delivered through an on-body infusor, intended for managing congestion in heart failure patients. The company's pipeline also encompasses scCeftriaxone, an antibiotic aimed at treating infections caused by both gram-positive and gram-negative bacteria, as well as the scCarbapenem program, another antibiotic designed for gram-negative bacterial infections. Additionally, scPharmaceuticals has entered into a collaboration agreement with West Pharmaceutical Services, Inc. for the advancement of a single-use SmartDose device. Founded in 2013, the company's main operations are based in Burlington, Massachusetts.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
SCHAEFFER LEONARD D U-Tender 43,104 2025-10-07
SCHAEFFER LEONARD D D-Return 19,750 $4.11 2025-10-07
SCHAEFFER LEONARD D D-Return 30,000 $3.85 2025-10-07
SCHAEFFER LEONARD D D-Return 16,300 $4.53 2025-10-07
VEITINGER KLAUS R DR D-Return 30,000 $3.85 2025-10-07

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms